share_log

Aditxt | 8-K: Current report

Aditxt | 8-K: Current report

Aditxt | 8-K：重大事件
美股SEC公告 ·  10/30 16:19

Moomoo AI 已提取核心信息

On October 28, 2024, Aditxt, Inc., a Delaware-based biotech company, entered into a significant agreement with Evofem Biosciences, Inc., purchasing 2,280 shares of Evofem Series F-1 Convertible Preferred Stock for $2,280,000. This transaction was accompanied by a Registration Rights Agreement, ensuring Evofem would file a registration statement for the resale of common stock issuable upon conversion of the preferred stock. The event also featured a fireside chat with Aditxt's CEO, Amro Albanna, and Evofem's CEO, Saundra Pelletier, moderated by Dr. Drew Pinsky. The discussion highlighted Aditxt's commitment to women's health, showcasing products like Phexxi®, a hormone-free contraceptive, and SOLOSEC®, a treatment for bacterial vaginosis and trichomoniasis. The conversation also touched on the potential for early detection of conditions like endometriosis through Aditxt's subsidiary, Pearsanta. The acquisition of Evofem by Aditxt is still in progress, pending the satisfaction of closing conditions, including the resolution of a senior loan.
On October 28, 2024, Aditxt, Inc., a Delaware-based biotech company, entered into a significant agreement with Evofem Biosciences, Inc., purchasing 2,280 shares of Evofem Series F-1 Convertible Preferred Stock for $2,280,000. This transaction was accompanied by a Registration Rights Agreement, ensuring Evofem would file a registration statement for the resale of common stock issuable upon conversion of the preferred stock. The event also featured a fireside chat with Aditxt's CEO, Amro Albanna, and Evofem's CEO, Saundra Pelletier, moderated by Dr. Drew Pinsky. The discussion highlighted Aditxt's commitment to women's health, showcasing products like Phexxi®, a hormone-free contraceptive, and SOLOSEC®, a treatment for bacterial vaginosis and trichomoniasis. The conversation also touched on the potential for early detection of conditions like endometriosis through Aditxt's subsidiary, Pearsanta. The acquisition of Evofem by Aditxt is still in progress, pending the satisfaction of closing conditions, including the resolution of a senior loan.
2024年10月28日，总部位于特拉华州的生物科技公司aditxt与evofem biosciences达成重要协议，以228万美元购买evofem f-1系列可转换优先股2280股。该交易附带注册权协议，确保evofem将为可转换优先股转换后发行的普通股提供注册声明。活动还设有一场炉边聊天，由aditxt的首席执行官Amro Albanna和evofem的首席执行官Saundra Pelletier进行，由Drew Pinsky博士主持。讨论突出了aditxt对女性健康的承诺，展示了产品如phexxi®（一种无激素避孕药）和solosec®（治疗细菌性阴道病和滴虫感染的药物）。对话还涉及通过aditxt的子公司Pearsanta实现对诸如子宫内膜异位症等疾病的早期检测的潜力。aditxt对evofem的收购仍在进行中，需要满足结束条件，包括解决一笔高级贷款。
2024年10月28日，总部位于特拉华州的生物科技公司aditxt与evofem biosciences达成重要协议，以228万美元购买evofem f-1系列可转换优先股2280股。该交易附带注册权协议，确保evofem将为可转换优先股转换后发行的普通股提供注册声明。活动还设有一场炉边聊天，由aditxt的首席执行官Amro Albanna和evofem的首席执行官Saundra Pelletier进行，由Drew Pinsky博士主持。讨论突出了aditxt对女性健康的承诺，展示了产品如phexxi®（一种无激素避孕药）和solosec®（治疗细菌性阴道病和滴虫感染的药物）。对话还涉及通过aditxt的子公司Pearsanta实现对诸如子宫内膜异位症等疾病的早期检测的潜力。aditxt对evofem的收购仍在进行中，需要满足结束条件，包括解决一笔高级贷款。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间